Search

Grants & abstract awards

EHA Travel GrantsThe call for travel grant applications will be open from January 1, 2025 until March 1, 2025 (23:59 CET). New: Grant applications have been integrated into the EHA2025 Abstract Submission form.

Read more

SWG Preceptorship Program

Funding to enable an SWG create its own preceptorship—and promote learning and innovation in our community. The call for proposals is open until 12:00 CEST on March 28, 2025. Apply now.

Read more

Accommodation

Welcome to the Hotel Accommodation page for the EHA2025 Congress. Hotel Information and Official Housing Bureau

INTERPLAN AG is the official housing bureau for the EHA2025 Congress.

Read more

EHA-Baltic Hematology Tutorial on Bleeding Disorders & Thrombosis

Dates: August 28-30, 2020 
Location: Riga, Latvia
Chairs: S Eichinger (EHA) & S Lejniece (LASH)

After a successful first edition, EHA is once again collaborating with the Latvian Society of Hematology (LASH), the Estonian Society of Hematology (EHS) and the Lithuanian Society of Hematology…

Read more

Highlights of Past EHA (HOPE) Asia 2020

EHA is returning to Sri Lanka for the 2nd edition of the Highlights of Past EHA (HOPE) Asia, organized with our hosting partner: the Sri Lanka College of Haematologists (SLCH).

Read more

EHA-SAH Hematology Tutorial on Acute Leukemia, MDS and BMF

Dates: September 11-12, 2020
Location: Buenos Aires, Argentina
Chairs: G Stemmelin, G Ossenkoppele

The third EHA-SAH Hematology Tutorial will be held in Buenos Aires, Argentina.

Read more

Epidemiology of infection in AML: A European Hematology Association survey (EPIAMLINF)

Project team

Jon Salmanton-García
Institution: University of Cologne, Germany

Biography: My research focuses on infectious diseases in hematology, particularly fungal infections and viral complications in immunocompromised patients.

Read more

From bedside to Brussels: hematology at the forefront of EU health policy

Access is at the heart of EHA's European Affairs work. More specifically, equitable and affordable access to innovative therapies that are of clear added benefit from a clinical, patient, and public health perspective.

Read more